Capital One National Association lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 71.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 31,086 shares of the company’s stock after selling 78,945 shares during the period. Capital One National Association’s holdings in Merck & Co., Inc. were worth $1,749,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. Heritage Investors Management Corp boosted its position in shares of Merck & Co., Inc. by 6.6% during the 4th quarter. Heritage Investors Management Corp now owns 238,488 shares of the company’s stock worth $13,420,000 after purchasing an additional 14,760 shares during the period. Boston Common Asset Management LLC lifted its holdings in Merck & Co., Inc. by 5.4% during the 4th quarter. Boston Common Asset Management LLC now owns 180,325 shares of the company’s stock worth $10,147,000 after buying an additional 9,312 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its holdings in Merck & Co., Inc. by 4.3% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 53,408 shares of the company’s stock worth $3,005,000 after buying an additional 2,216 shares in the last quarter. Ffcm LLC lifted its holdings in Merck & Co., Inc. by 24.5% during the 4th quarter. Ffcm LLC now owns 185,294 shares of the company’s stock worth $10,426,000 after buying an additional 36,436 shares in the last quarter. Finally, Doyle Wealth Management lifted its holdings in Merck & Co., Inc. by 30.8% during the 4th quarter. Doyle Wealth Management now owns 110,323 shares of the company’s stock worth $6,208,000 after buying an additional 25,953 shares in the last quarter. 74.63% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Weir Mirian M. Graddick sold 60,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the sale, the insider now directly owns 101,484 shares in the company, valued at approximately $6,254,458.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Weir Mirian M. Graddick sold 5,000 shares of Merck & Co., Inc. stock in a transaction on Friday, January 12th. The stock was sold at an average price of $58.00, for a total transaction of $290,000.00. Following the sale, the insider now owns 101,484 shares in the company, valued at $5,886,072. The disclosure for this sale can be found here. Insiders sold a total of 82,500 shares of company stock worth $5,026,025 over the last 90 days. Company insiders own 0.25% of the company’s stock.
Shares of MRK opened at $53.36 on Friday. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $66.41. The firm has a market capitalization of $147,023.23, a PE ratio of 13.41, a PEG ratio of 2.30 and a beta of 0.78. The company has a current ratio of 1.33, a quick ratio of 1.06 and a debt-to-equity ratio of 0.62.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.04. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The business had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. During the same period last year, the business earned $0.89 EPS. The company’s revenue was up 3.1% on a year-over-year basis. equities analysts expect that Merck & Co., Inc. will post 4.16 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 6th. Stockholders of record on Thursday, March 15th were issued a $0.48 dividend. The ex-dividend date was Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.60%. Merck & Co., Inc.’s payout ratio is 48.24%.
A number of equities research analysts have issued reports on the stock. BMO Capital Markets set a $65.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Friday. Barclays upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $62.00 to $64.00 in a report on Thursday. Jefferies Group set a $55.00 target price on shares of Merck & Co., Inc. and gave the stock a “hold” rating in a report on Friday, March 23rd. Leerink Swann upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating in a report on Monday, March 12th. Finally, Credit Suisse Group reduced their target price on shares of Merck & Co., Inc. from $66.00 to $65.00 and set an “outperform” rating on the stock in a report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus target price of $66.47.
COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/merck-co-inc-mrk-shares-sold-by-capital-one-national-association.html.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.